Another clinical trial aimed to elucidate the potential of pegylated IFNα-2a compared to Hydroxyurea (HU) in PV and ET patients (ClinicalTrials.gov Identifier: NCT01259856) [133]. Here, IFNA2 is linked to acquired polycythemia vera.